Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use.


Journal

Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543

Informations de publication

Date de publication:
12 2019
Historique:
received: 19 12 2018
accepted: 13 06 2019
pubmed: 2 11 2019
medline: 31 1 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

To analyze the relationship between atrial fibrillation (AF) and Charlson comorbidity index (CCI) in a population-based cohort study over a long-term follow-up period, in relation to oral anticoagulant (OAC) prescriptions and outcomes. We used data from the administrative health databases of Lombardy. All patients with AF and age 40 years and older and who were admitted to the hospital in 2002 were considered for analysis and followed up to 2014. AF diagnosis and CCI were established according to codes from the International Classification of Diseases, Ninth Revision. In 2002, 24,040 patients were admitted with a diagnosis of AF. CCI was higher in patients with AF than in those without AF (1.8±2.1 vs 0.2±0.9; P<.001). Over 12 years of follow-up, AF was associated with an increased risk of higher CCI (beta coefficient, 1.69; 95% CI, 1.67-1.70). In patients with AF, CCI was inversely associated with OAC prescription at baseline (P<.001) and at the end of the follow-up (P=.03). Patients with AF and a high CCI (≥4) had a higher cumulative incidence of stroke, major bleeding, and all-cause death (all P<.001), compared with those with low CCI (range, 0-3). Adjusted Cox regression analysis revealed that time-dependent continuous CCI was associated with an increased risk for stroke, major bleeding, and all-cause death (all P<.001). In hospitalized patients, AF is associated with an increase in CCI that is inversely associated with OAC prescriptions during follow-up. CCI is independently associated with an increased risk of stroke, major bleeding, and all-cause death.

Identifiants

pubmed: 31668449
pii: S0025-6196(19)30628-7
doi: 10.1016/j.mayocp.2019.06.012
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2427-2436

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Marco Proietti (M)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. Electronic address: marco.proietti@unimi.it.

Irene Marzona (I)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Tommaso Vannini (T)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Mauro Tettamanti (M)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Ida Fortino (I)

Regional Ministry of Health, Lombardy Region, Milan, Italy.

Luca Merlino (L)

Regional Ministry of Health, Lombardy Region, Milan, Italy.

Stefania Basili (S)

Department of Translational and Precision Medicine, Sapienza-University of Rome, Rome, Italy.

Pier Mannuccio Mannucci (PM)

Scientific Direction, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Giuseppe Boriani (G)

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Maria Carla Roncaglioni (MC)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Alessandro Nobili (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH